Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients
Oxidative stress-mediated cell damage has been considered in the pathophysiology of schizophrenia. Abnormal findings have often been considered related to differences in ethnicity, life style, dietary patterns and medications, all of which influence indices of oxidative stress and oxidative cell dam...
Saved in:
Published in | Psychiatry research Vol. 121; no. 2; pp. 109 - 122 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Shannon
Elsevier Ireland Ltd
01.12.2003
Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 0165-1781 1872-7123 |
DOI | 10.1016/S0165-1781(03)00220-8 |
Cover
Abstract | Oxidative stress-mediated cell damage has been considered in the pathophysiology of schizophrenia. Abnormal findings have often been considered related to differences in ethnicity, life style, dietary patterns and medications, all of which influence indices of oxidative stress and oxidative cell damage. To minimize these confounds, schizophrenic patients were compared with age-matched control subjects with the same ethnic background and similar lifestyle, as well as with bipolar mood disorder (BMD) patients. Levels of antioxidant defense enzymes (i.e. superoxide dismutase, SOD; catalase, CAT; and glutathione peroxidase, GPx) were lower in schizophrenic patients than in controls, indicating conditions for increased oxidative stress. The contents of plasma thiobarbituric acid reactive substances (TBARS) were only marginally higher in schizophrenic patients, who had normal levels of arachidonic acid (AA), a major source of TBARS, indicating no significant oxidative membrane lipid peroxidation. Levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), however, were significantly lower in schizophrenic patients. When the same indices in BMD patients were compared with findings in matched controls, levels of only SOD and CAT were lower in the patients, whereas GPx was not. Again, as in schizophrenia, the contents of TBARS were marginally higher in BMD patients with no change in levels of AA. Levels of alpha-linolenic acid and EPA were significantly lower and levels of DHA were slightly lower in BMD patients. These data indicate that certain biochemical characteristics may be common to a spectrum of psychiatric disorders, and suggest supplementation of antioxidants and essential fatty acids might affect clinical outcome. |
---|---|
AbstractList | Oxidative stress-mediated cell damage has been considered in the pathophysiology of schizophrenia. Abnormal findings have often been considered related to differences in ethnicity, life style, dietary patterns and medications, all of which influence indices of oxidative stress and oxidative cell damage. To minimize these confounds, schizophrenic patients were compared with age-matched control subjects with the same ethnic background and similar lifestyle, as well as with bipolar mood disorder (BMD) patients. Levels of antioxidant defense enzymes (i.e. superoxide dismutase, SOD; catalase, CAT; and glutathione peroxidase, GPx) were lower in schizophrenic patients than in controls, indicating conditions for increased oxidative stress. The contents of plasma thiobarbituric acid reactive substances (TBARS) were only marginally higher in schizophrenic patients, who had normal levels of arachidonic acid (AA), a major source of TBARS, indicating no significant oxidative membrane lipid peroxidation. Levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), however, were significantly lower in schizophrenic patients. When the same indices in BMD patients were compared with findings in matched controls, levels of only SOD and CAT were lower in the patients, whereas GPx was not. Again, as in schizophrenia, the contents of TBARS were marginally higher in BMD patients with no change in levels of AA. Levels of alpha-linolenic acid and EPA were significantly lower and levels of DHA were slightly lower in BMD patients. These data indicate that certain biochemical characteristics may be common to a spectrum of psychiatric disorders, and suggest supplementation of antioxidants and essential fatty acids might affect clinical outcome.Oxidative stress-mediated cell damage has been considered in the pathophysiology of schizophrenia. Abnormal findings have often been considered related to differences in ethnicity, life style, dietary patterns and medications, all of which influence indices of oxidative stress and oxidative cell damage. To minimize these confounds, schizophrenic patients were compared with age-matched control subjects with the same ethnic background and similar lifestyle, as well as with bipolar mood disorder (BMD) patients. Levels of antioxidant defense enzymes (i.e. superoxide dismutase, SOD; catalase, CAT; and glutathione peroxidase, GPx) were lower in schizophrenic patients than in controls, indicating conditions for increased oxidative stress. The contents of plasma thiobarbituric acid reactive substances (TBARS) were only marginally higher in schizophrenic patients, who had normal levels of arachidonic acid (AA), a major source of TBARS, indicating no significant oxidative membrane lipid peroxidation. Levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), however, were significantly lower in schizophrenic patients. When the same indices in BMD patients were compared with findings in matched controls, levels of only SOD and CAT were lower in the patients, whereas GPx was not. Again, as in schizophrenia, the contents of TBARS were marginally higher in BMD patients with no change in levels of AA. Levels of alpha-linolenic acid and EPA were significantly lower and levels of DHA were slightly lower in BMD patients. These data indicate that certain biochemical characteristics may be common to a spectrum of psychiatric disorders, and suggest supplementation of antioxidants and essential fatty acids might affect clinical outcome. Oxidative stress-mediated cell damage has been considered in the pathophysiology of schizophrenia. Abnormal findings have often been considered related to differences in ethnicity, life style, dietary patterns and medications, all of which influence indices of oxidative stress and oxidative cell damage. To minimize these confounds, schizophrenic patients were compared with age-matched control subjects with the same ethnic background and similar lifestyle, as well as with bipolar mood disorder (BMD) patients. Levels of antioxidant defense enzymes (i.e. superoxide dismutase, SOD; catalase, CAT; and glutathione peroxidase, GPx) were lower in schizophrenic patients than in controls, indicating conditions for increased oxidative stress. The contents of plasma thiobarbituric acid reactive substances (TBARS) were only marginally higher in schizophrenic patients, who had normal levels of arachidonic acid (AA), a major source of TBARS, indicating no significant oxidative membrane lipid peroxidation. Levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), however, were significantly lower in schizophrenic patients. When the same indices in BMD patients were compared with findings in matched controls, levels of only SOD and CAT were lower in the patients, whereas GPx was not. Again, as in schizophrenia, the contents of TBARS were marginally higher in BMD patients with no change in levels of AA. Levels of alpha-linolenic acid and EPA were significantly lower and levels of DHA were slightly lower in BMD patients. These data indicate that certain biochemical characteristics may be common to a spectrum of psychiatric disorders, and suggest supplementation of antioxidants and essential fatty acids might affect clinical outcome. |
Author | Hegde, Mahabaleshwar V Ghate, Madhav Debsikdar, Vijay B Sitasawad, Sandhya Wagh, Ulhas V Mahadik, Sahebarao P Hinge, Ashwini Kale, Anvita Ranjekar, Prabhakar K |
Author_xml | – sequence: 1 givenname: Prabhakar K surname: Ranjekar fullname: Ranjekar, Prabhakar K organization: National Chemical Laboratory, Homi Bhabha Road, Pune 411008, India – sequence: 2 givenname: Ashwini surname: Hinge fullname: Hinge, Ashwini organization: National Chemical Laboratory, Homi Bhabha Road, Pune 411008, India – sequence: 3 givenname: Mahabaleshwar V surname: Hegde fullname: Hegde, Mahabaleshwar V organization: National Chemical Laboratory, Homi Bhabha Road, Pune 411008, India – sequence: 4 givenname: Madhav surname: Ghate fullname: Ghate, Madhav organization: MIMER Medical College, Talegaon, India – sequence: 5 givenname: Anvita surname: Kale fullname: Kale, Anvita organization: National Chemical Laboratory, Homi Bhabha Road, Pune 411008, India – sequence: 6 givenname: Sandhya surname: Sitasawad fullname: Sitasawad, Sandhya organization: National Center for Cell Science, Ganeshkhind Road, Pune 411007, India – sequence: 7 givenname: Ulhas V surname: Wagh fullname: Wagh, Ulhas V organization: Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune 411043, India – sequence: 8 givenname: Vijay B surname: Debsikdar fullname: Debsikdar, Vijay B organization: Kripamayee Research Center, Kripamayee Institute for Mental Health, Miraj, India – sequence: 9 givenname: Sahebarao P surname: Mahadik fullname: Mahadik, Sahebarao P email: mahadik@psychnts4.mcg.edu organization: Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune 411043, India |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15331114$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/14656446$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkU1v1DAQhi1URLeFnwDyBQSHgO04HyuEKlQ-pUocgLM1sSeqIYm3toOanvnhTHeXIvVSfPBI9vO-o5n3iB1MYULGHkvxUgpZv_pKV1XIppXPRflCCKVE0d5jK9k2qmikKg_Y6gY5ZEcp_RBEyfX6ATuUuq5qresV-_0ObURI6DhM2YdL76hynK6WERO9OT7i2EWYkGNKSAwMfBOGZZ4S5DlCJmkPOS8crHeJ-4kne-6vwuY84uTt1qPzJIHIxxAcdz6F6DDyDWRPjukhu9_DkPDRvh6z7x_efzv9VJx9-fj59O1ZYSspc9F3yjqsQSldguirVnSVkKB006keaHBZ6lpL-tZO6BbXsrFO0oFS91VVlcfs2c53E8PFjCmb0SeLw0DThTmZRmq1blRJ4JM9OHcjOrOJfoS4mL97I-DpHoBkYehpP9anf1xVltRXE_d6x9kYUorYG-szTR2mHMEPRgpznabZpmmuozKiNNs0TUvq6pb6psEdupOdDmmZvzxGkywt2qLzEW02Lvg7Hd7ccrCDpzBh-InLf-j_AM9gy0w |
CODEN | PSRSDR |
CitedBy_id | crossref_primary_10_1016_j_jad_2013_11_008 crossref_primary_10_1080_08039488_2021_2016954 crossref_primary_10_1016_j_biopsych_2005_01_002 crossref_primary_10_1016_j_braindev_2011_01_002 crossref_primary_10_1016_j_jpsychires_2016_05_014 crossref_primary_10_1186_1471_244X_5_37 crossref_primary_10_1016_j_immbio_2012_06_003 crossref_primary_10_1016_j_neuropharm_2011_12_014 crossref_primary_10_3389_fphys_2024_1399154 crossref_primary_10_1080_1028415X_2018_1478766 crossref_primary_10_1134_S2079086414050065 crossref_primary_10_1016_j_phrs_2012_06_010 crossref_primary_10_2478_v10011_010_0018_7 crossref_primary_10_1093_schbul_sbaa062 crossref_primary_10_1016_j_pnpbp_2006_12_019 crossref_primary_10_1016_j_mhpa_2009_09_001 crossref_primary_10_1016_j_neuint_2013_02_001 crossref_primary_10_1586_ern_12_64 crossref_primary_10_1016_j_pnpbp_2005_11_034 crossref_primary_10_1517_14728222_2014_940893 crossref_primary_10_1016_j_jpsychires_2013_03_014 crossref_primary_10_1016_j_pbiomolbio_2024_11_002 crossref_primary_10_1371_journal_pone_0183812 crossref_primary_10_1186_2049_9256_1_2 crossref_primary_10_1016_j_eurpsy_2017_02_479 crossref_primary_10_1016_j_pnpbp_2013_04_020 crossref_primary_10_1017_S146114571000146X crossref_primary_10_1093_schbul_sbv133 crossref_primary_10_1186_s12944_016_0196_5 crossref_primary_10_1111_eip_12282 crossref_primary_10_1016_j_psychres_2006_04_011 crossref_primary_10_1016_j_psychres_2018_09_009 crossref_primary_10_1016_j_biopsych_2013_03_018 crossref_primary_10_1007_s12035_015_9174_6 crossref_primary_10_1016_j_pnpbp_2008_07_001 crossref_primary_10_1016_j_pnpbp_2011_12_006 crossref_primary_10_1016_S1995_7645_10_60017_X crossref_primary_10_1111_j_1469_7610_2010_02235_x crossref_primary_10_1016_j_jpsychires_2008_11_005 crossref_primary_10_1016_j_pnpbp_2009_11_024 crossref_primary_10_3390_cryst10030148 crossref_primary_10_1016_j_fra_2013_03_005 crossref_primary_10_1111_pcn_12852 crossref_primary_10_1093_schbul_sbt045 crossref_primary_10_1586_14737175_2013_811981 crossref_primary_10_1016_j_pnpbp_2012_05_005 crossref_primary_10_1111_bdi_12386 crossref_primary_10_3389_fpsyt_2021_792560 crossref_primary_10_1016_j_euroneuro_2010_06_016 crossref_primary_10_1016_j_neuroscience_2016_01_067 crossref_primary_10_1080_00325481_2021_2006514 crossref_primary_10_3390_jcm11206060 crossref_primary_10_1016_j_jpsychires_2007_05_009 crossref_primary_10_1017_S1461145713001740 crossref_primary_10_4103_0019_5545_70974 crossref_primary_10_1016_j_jad_2014_10_014 crossref_primary_10_1089_act_2005_11_241 crossref_primary_10_1016_S1134_5934_09_71893_7 crossref_primary_10_1017_S1461145713000096 crossref_primary_10_1111_pcn_12163 crossref_primary_10_1177_0897190011422876 crossref_primary_10_1111_j_1399_5618_2006_00372_x crossref_primary_10_1016_j_pnpbp_2011_08_018 crossref_primary_10_1007_s11064_006_9070_6 crossref_primary_10_1016_S1734_1140_13_71517_2 crossref_primary_10_1016_j_jpsychires_2013_06_018 crossref_primary_10_17546_msd_488247 crossref_primary_10_9758_cpn_2015_13_2_129 crossref_primary_10_1586_ern_12_98 crossref_primary_10_1080_08039488_2018_1441906 crossref_primary_10_1177_2045125319869791 crossref_primary_10_4103_0019_5545_146516 crossref_primary_10_1016_j_schres_2012_03_004 crossref_primary_10_4236_ijcm_2012_37104 crossref_primary_10_1016_j_psychres_2012_09_041 crossref_primary_10_1007_s11064_010_0195_2 crossref_primary_10_1007_s00406_007_0797_0 crossref_primary_10_1016_S0034_7450_14_60201_8 crossref_primary_10_1186_2045_9912_3_11 crossref_primary_10_1007_s11064_006_9162_3 crossref_primary_10_1016_j_psychres_2015_09_035 crossref_primary_10_1016_j_biopsych_2011_02_011 crossref_primary_10_1016_j_jpsychires_2008_01_010 crossref_primary_10_1016_j_ijmm_2013_11_018 crossref_primary_10_1186_1471_244X_12_52 crossref_primary_10_1016_j_pnpbp_2010_11_032 crossref_primary_10_1016_j_psychres_2020_113467 crossref_primary_10_1124_jpet_116_237503 crossref_primary_10_1016_j_jad_2024_03_114 crossref_primary_10_1016_j_ajp_2017_12_006 crossref_primary_10_1016_j_jad_2008_08_011 crossref_primary_10_1016_j_brainresbull_2016_10_008 crossref_primary_10_1016_j_jpsychires_2009_08_001 crossref_primary_10_1016_j_mehy_2006_07_054 crossref_primary_10_1016_j_schres_2013_11_010 crossref_primary_10_1111_j_1440_1819_2009_02015_x crossref_primary_10_1016_j_jad_2008_04_013 crossref_primary_10_1016_j_niox_2020_11_001 crossref_primary_10_1016_j_psychres_2015_04_046 crossref_primary_10_1002_ajmg_b_31112 crossref_primary_10_1016_j_schres_2024_05_018 crossref_primary_10_4103_0019_5545_43627 crossref_primary_10_1007_s00213_016_4500_x crossref_primary_10_1016_j_psychres_2006_03_025 crossref_primary_10_1111_j_1751_7893_2007_00021_x crossref_primary_10_1016_j_plefa_2009_05_017 crossref_primary_10_2174_2666082218666220822154558 crossref_primary_10_1016_j_jpsychires_2012_08_010 crossref_primary_10_1177_0269881119845820 crossref_primary_10_2174_1566524023666230904150907 crossref_primary_10_1016_j_jpsychires_2006_07_013 crossref_primary_10_1016_j_schres_2012_08_014 crossref_primary_10_36290_psy_2019_014 crossref_primary_10_1016_j_jpsychires_2013_11_011 crossref_primary_10_62482_pmj_26 crossref_primary_10_1177_070674370705201202 crossref_primary_10_1016_j_bbr_2025_115528 crossref_primary_10_1016_j_pnpbp_2017_08_024 crossref_primary_10_1016_j_pnpbp_2012_10_017 crossref_primary_10_1007_s12011_014_0067_8 crossref_primary_10_1016_j_metabol_2011_02_001 crossref_primary_10_1016_j_jad_2020_05_001 crossref_primary_10_1016_j_pnpbp_2006_03_009 crossref_primary_10_1016_j_clinph_2013_05_021 crossref_primary_10_1016_j_jpsychires_2012_11_004 crossref_primary_10_1016_j_rpsm_2018_03_003 crossref_primary_10_3390_medicines9110057 crossref_primary_10_1007_s00232_010_9267_0 crossref_primary_10_1016_j_jpsychires_2014_07_028 crossref_primary_10_1017_S0954422408998620 crossref_primary_10_1021_jf073471e crossref_primary_10_1016_j_psychres_2017_02_016 crossref_primary_10_1021_acschemneuro_2c00420 crossref_primary_10_1016_j_schres_2013_02_001 crossref_primary_10_1111_j_1399_5618_2010_00827_x crossref_primary_10_1186_1471_244X_11_26 crossref_primary_10_3109_13651501_2015_1016973 crossref_primary_10_2217_bmm_13_83 crossref_primary_10_1016_j_schres_2015_06_022 crossref_primary_10_1016_j_jneuroim_2016_10_012 crossref_primary_10_1097_00041444_200409000_00012 crossref_primary_10_1016_j_pharmthera_2020_107520 crossref_primary_10_1016_j_psychres_2007_08_021 crossref_primary_10_4103_0019_5545_64590 crossref_primary_10_1007_s11011_009_9160_7 crossref_primary_10_1016_j_pnpbp_2017_05_005 crossref_primary_10_1016_j_psychres_2013_10_011 crossref_primary_10_1016_j_ejpsy_2020_08_001 crossref_primary_10_1016_j_neubiorev_2025_106005 crossref_primary_10_1155_2014_828702 crossref_primary_10_1097_PSY_0000000000000931 crossref_primary_10_1017_S1461145707008401 crossref_primary_10_2165_11539700_000000000_00000 crossref_primary_10_1016_j_ibneur_2023_11_007 crossref_primary_10_1016_j_jprot_2016_04_034 crossref_primary_10_3390_antiox9080714 crossref_primary_10_1586_ern_09_31 crossref_primary_10_1186_s12888_014_0268_x crossref_primary_10_1016_j_pharep_2014_12_015 crossref_primary_10_1016_j_pnpbp_2006_06_011 crossref_primary_10_1016_j_psychres_2013_05_006 crossref_primary_10_1007_s00213_013_3397_x crossref_primary_10_1002_ajhb_21129 crossref_primary_10_3389_fcell_2021_615569 crossref_primary_10_1016_j_enzmictec_2005_08_040 crossref_primary_10_1124_pr_107_00107 crossref_primary_10_1016_j_plefa_2010_07_001 crossref_primary_10_3390_antiox11101870 crossref_primary_10_1007_s11033_020_05354_1 crossref_primary_10_3390_brainsci14121199 crossref_primary_10_1016_j_pnpbp_2006_09_012 crossref_primary_10_1016_j_schres_2005_05_019 crossref_primary_10_1016_j_schres_2007_09_036 crossref_primary_10_30773_pi_2016_12_31 crossref_primary_10_1016_j_pnpbp_2012_07_013 crossref_primary_10_1007_s10528_024_10986_0 crossref_primary_10_1007_s12264_022_00871_4 crossref_primary_10_1089_ars_2010_3508 crossref_primary_10_1016_j_ijdevneu_2010_02_002 crossref_primary_10_1111_j_1601_183X_2011_00712_x crossref_primary_10_1002_jnr_20875 crossref_primary_10_1016_j_jtemb_2024_127532 crossref_primary_10_1016_j_pnpbp_2013_02_015 crossref_primary_10_1002_hup_2453 crossref_primary_10_1016_j_pnpbp_2013_02_007 crossref_primary_10_1177_0004563214528882 crossref_primary_10_1016_j_neuint_2020_104877 crossref_primary_10_1016_j_pnpbp_2007_08_003 crossref_primary_10_1016_j_mehy_2011_03_051 crossref_primary_10_1016_j_tins_2008_07_007 crossref_primary_10_1016_j_phanu_2012_10_004 crossref_primary_10_1016_j_mehy_2020_110433 crossref_primary_10_1586_ern_11_42 crossref_primary_10_1016_j_neulet_2009_12_072 crossref_primary_10_1186_s12991_021_00354_2 crossref_primary_10_1016_j_psc_2015_10_003 crossref_primary_10_1007_s11011_018_0209_3 crossref_primary_10_1007_s12640_016_9621_9 crossref_primary_10_3389_fdmed_2025_1542913 crossref_primary_10_1016_j_plefa_2006_07_009 crossref_primary_10_1016_j_plefa_2006_07_008 crossref_primary_10_2174_1381612826666201113095938 crossref_primary_10_1002_hup_2272 crossref_primary_10_1177_0269881117731169 crossref_primary_10_4236_ojpsych_2011_11001 crossref_primary_10_1016_j_jpsychires_2011_10_004 crossref_primary_10_1016_j_neubiorev_2010_10_008 crossref_primary_10_1016_j_plefa_2006_07_010 crossref_primary_10_1016_j_schres_2005_10_011 crossref_primary_10_1155_2024_9979582 crossref_primary_10_1007_s12031_018_1165_4 crossref_primary_10_1002_jnr_20570 crossref_primary_10_1093_ajcn_85_6_1665 crossref_primary_10_9758_cpn_23_1084 crossref_primary_10_1016_j_bpsgos_2023_07_004 crossref_primary_10_3109_00365513_2013_873947 crossref_primary_10_1038_sj_mp_4001888 crossref_primary_10_1016_j_psychres_2008_10_038 crossref_primary_10_1111_j_1440_1819_2010_02178_x crossref_primary_10_1515_cclm_2015_0212 crossref_primary_10_3390_medicina58101491 crossref_primary_10_1002_ajmg_b_30791 crossref_primary_10_1016_j_plefa_2008_11_004 crossref_primary_10_1016_j_ncl_2015_08_011 crossref_primary_10_3892_br_2018_1040 crossref_primary_10_1016_j_jpsychires_2006_04_006 crossref_primary_10_1038_sj_npp_1301628 crossref_primary_10_1017_S1461145709990654 crossref_primary_10_3389_fpsyt_2021_546801 crossref_primary_10_1016_j_ejphar_2006_03_076 crossref_primary_10_1016_j_neubiorev_2017_08_025 crossref_primary_10_1007_s40263_016_0343_6 crossref_primary_10_1177_0884533611411306 crossref_primary_10_1007_s12035_018_1051_7 crossref_primary_10_1016_j_pnpbp_2007_03_008 crossref_primary_10_1016_j_psyneuen_2014_09_029 crossref_primary_10_1002_prca_200700230 crossref_primary_10_1016_j_psychres_2014_04_005 crossref_primary_10_3109_15622975_2010_526146 crossref_primary_10_1016_j_psychres_2009_01_017 crossref_primary_10_1016_j_jpsychires_2006_11_004 crossref_primary_10_1111_j_1399_5618_2007_00387_x crossref_primary_10_1016_j_psychres_2009_01_013 crossref_primary_10_1016_j_pnpbp_2012_06_013 crossref_primary_10_1007_s12011_020_02346_x crossref_primary_10_1080_01480545_2023_2219039 crossref_primary_10_3389_fnut_2019_00076 crossref_primary_10_1016_j_jad_2007_11_002 crossref_primary_10_1177_0960327113493305 crossref_primary_10_1016_j_immbio_2012_10_005 crossref_primary_10_1016_j_pnpbp_2017_01_007 crossref_primary_10_1016_j_neulet_2006_08_026 crossref_primary_10_1186_1471_244X_11_124 crossref_primary_10_3390_brainsci11070917 crossref_primary_10_4103_0019_5545_39753 crossref_primary_10_1080_15622970801901802 crossref_primary_10_1016_j_neulet_2007_05_016 crossref_primary_10_1016_j_neubiorev_2007_10_005 crossref_primary_10_1016_j_rpsmen_2018_03_001 crossref_primary_10_1002_dneu_22329 crossref_primary_10_1016_j_psychres_2010_07_049 crossref_primary_10_1002_biof_1093 crossref_primary_10_1016_j_neulet_2016_02_031 crossref_primary_10_1002_ajmg_b_30776 crossref_primary_10_1515_cclm_2013_0978 crossref_primary_10_1016_j_plefa_2006_02_001 crossref_primary_10_1016_j_pnpbp_2009_06_018 crossref_primary_10_1016_j_psychres_2006_05_025 crossref_primary_10_1016_j_pnpbp_2006_12_020 crossref_primary_10_1002_hbm_21438 crossref_primary_10_1016_j_biopsych_2005_04_052 crossref_primary_10_1016_j_plefa_2007_10_006 crossref_primary_10_1080_09540260600581993 |
Cites_doi | 10.1016/S0920-9964(97)00005-4 10.1016/S0920-9964(01)00334-6 10.1017/S0264180100000904 10.2466/pr0.1962.10.3.799 10.1176/ajp.150.9.1405 10.1001/archpsyc.56.5.407 10.1016/0003-2697(79)90738-3 10.1001/archpsyc.1988.01800320058007 10.1016/S0022-3956(02)00048-1 10.1016/S0022-3956(01)00048-6 10.1016/0165-1781(96)02899-5 10.1093/clinchem/32.5.805 10.1016/S0165-1781(99)00014-1 10.1176/ajp.149.1.22 10.1093/ajcn/54.3.438 10.1016/S0149-7634(05)80180-0 10.1176/appi.ajp.159.3.477 10.1111/j.1471-4159.1984.tb02728.x 10.1016/0006-291X(91)91228-5 10.1017/S0033291700032797 10.1093/schbul/11.3.471 10.1093/schbul/12.1.52 10.1016/S0920-9964(97)00151-5 10.1016/0920-9964(94)90084-1 10.1016/0006-3223(91)90298-Z 10.2165/00023210-200115040-00004 10.1002/cbf.940 10.1016/S0278-5846(02)00220-8 10.1016/S0920-9964(99)00095-X 10.1016/S0006-3223(99)00092-X 10.1111/j.1600-0447.1988.tb06388.x 10.1016/S0006-3223(02)01443-9 10.1016/S0920-9964(02)00284-0 10.1016/S0952-3278(96)90147-7 10.1001/archpsyc.1982.04290070025006 10.1016/0920-9964(94)90043-4 10.1176/ajp.145.5.578 10.1016/j.plefa.2003.08.010 10.1192/bjp.156.6.788 10.1016/0920-9964(95)00048-8 10.1001/archpsyc.1988.01800280038006 10.1016/S0278-5846(00)00181-0 10.1016/0006-2952(94)00424-K 10.1016/S0952-3278(96)90142-8 10.1176/appi.ajp.158.9.1449 10.1016/S0022-3956(98)00028-4 10.1001/archpsyc.1993.01820230041004 10.1016/S0952-3278(96)90143-X 10.1016/0006-3223(90)90461-A 10.1093/schbul/14.2.291 10.1016/0920-9964(95)00049-6 10.1016/S0920-9964(02)00328-6 10.1016/0165-1781(93)90054-K 10.1016/S0952-3278(96)90144-1 10.1016/0006-3223(90)90490-S 10.1016/S0006-3223(97)00282-5 10.1097/00004850-199300830-00003 10.1093/schbul/13.2.261 |
ContentType | Journal Article |
Copyright | 2003 Elsevier Ireland Ltd 2004 INIST-CNRS |
Copyright_xml | – notice: 2003 Elsevier Ireland Ltd – notice: 2004 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/S0165-1781(03)00220-8 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1872-7123 |
EndPage | 122 |
ExternalDocumentID | 14656446 15331114 10_1016_S0165_1781_03_00220_8 S0165178103002208 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29P 4.4 457 4G. 53G 5VS 7-5 71M 8P~ 9JM 9JO AABNK AADFP AAEDT AAEDW AAGJA AAGKA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABIVO ABJNI ABMAC ABMZM ABOYX ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACIUM ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEG HMK HMO HMQ HMW HVGLF HZ~ IHE J1W KOM M29 M2V M39 M3V M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPS SSB SSH SSN SSY SSZ T5K UV1 WUQ Z5R ZGI ~G- AACTN AADPK AAIAV ABLVK ABYKQ AFCTW AFKWA AFYLN AJBFU AJOXV AMFUW EFLBG LCYCR RIG ZA5 AAYXX ACLOT CITATION ~HD AAPBV ABPIF ABPTK IQODW CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c511t-fb2cde6a2243a0f580b501a247b2fa1871346412244d048e917cd1111a34f5553 |
IEDL.DBID | .~1 |
ISSN | 0165-1781 |
IngestDate | Sat Sep 27 17:42:58 EDT 2025 Wed Feb 19 02:33:24 EST 2025 Sun Oct 22 16:05:42 EDT 2023 Thu Apr 24 23:11:05 EDT 2025 Wed Oct 01 04:10:04 EDT 2025 Fri Feb 23 02:26:41 EST 2024 Tue Aug 26 16:35:33 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Schizophrenia Bipolar mood disorder Essential fatty acids Antioxidant enzymes Lipid peroxides Mood disorder Glutathione peroxidase Human Oxidative stress Biochemical analysis Pathophysiology Enzyme Polyunsaturated fatty acid Biological marker Lipids Superoxide dismutase Bipolar disorder Antioxidant n-3 fatty acid Psychosis Blood concentration n-6 fatty acid Peroxidases Catalase Unsaturated fatty acid Oxidoreductases Comparative study |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c511t-fb2cde6a2243a0f580b501a247b2fa1871346412244d048e917cd1111a34f5553 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 14656446 |
PQID | 71429723 |
PQPubID | 23479 |
PageCount | 14 |
ParticipantIDs | proquest_miscellaneous_71429723 pubmed_primary_14656446 pascalfrancis_primary_15331114 crossref_citationtrail_10_1016_S0165_1781_03_00220_8 crossref_primary_10_1016_S0165_1781_03_00220_8 elsevier_sciencedirect_doi_10_1016_S0165_1781_03_00220_8 elsevier_clinicalkey_doi_10_1016_S0165_1781_03_00220_8 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2003-12-01 |
PublicationDateYYYYMMDD | 2003-12-01 |
PublicationDate_xml | – month: 12 year: 2003 text: 2003-12-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Shannon |
PublicationPlace_xml | – name: Shannon – name: Ireland |
PublicationTitle | Psychiatry research |
PublicationTitleAlternate | Psychiatry Res |
PublicationYear | 2003 |
Publisher | Elsevier Ireland Ltd Elsevier |
Publisher_xml | – name: Elsevier Ireland Ltd – name: Elsevier |
References | McCreadie, MacDonald, Wiles, Campbell, Pateson (BIB51) 1995; 170 Evans, D.R., Parikh, V.V., Khan, M.M., Coussons, C., Buckley, P.F., Mahadik, S.P., 2003. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids, in press Lohr, Cadet, Lohr, Larson, Wasli, Wade, Hylton, Vidoni, Jeste, Wyatt (BIB37) 1988; 14 Glen, Glen, Horrobin, Vaddadi, Spellman, Morse-Fischer, Ellis, Skinner (BIB22) 1994; 12 Crow (BIB15) 1985; 11 Wainwright (BIB70) 1992; 16 Adler, Peselow, Rotrosen, Duncan, Lee, Rosenthal, Angrist (BIB2) 1993; 150 Peet, Horrobin (BIB57) 2002; 36 (BIB5) 1994 Fenton, Hibbeln, Knable (BIB20) 2000; 47 Subramanyam, Pond, Eyles, Whiteford, Founda, Castagnoli (BIB68) 1991; 181 Arvindakshan, Sitasawad, Debsikdar, Ghate, Horrobin, Bennett, Ranjekar, Mahadik (BIB10) 2003; 53 Kahlbaum, K., 1963. Die Gruppirung der Psychischen Krankheiten und die Eintheilung der Seelenstorungen. AW Kafemann, Danzing Andreasen, Olsen (BIB6) 1982; 39 Jablensky, Häfner (BIB26) 1986; 40 Mahadik, Mukherjee, Correnti, Scheffer, Mahadik (BIB47) 1998; 43 Mahadik, Mukherjee (BIB43) 1996; 19 Khan, Khan, Leventhal, Brown (BIB31) 2001; 158 Arvindakshan, M., 2003. Ph.D. Thesis: The Role of Membrane Essential Polyunsaturated Fatty Acids in Schizophrenia Outcome. Pune University Press, Pune, India Parikh, Khan, Mahadik (BIB56) 2002; 37 Roy, Pathak, Singh (BIB63) 1984; 42 Ramchand, Davies, Tresman, Griffiths, Peet (BIB60) 1996; 55 Khan, Evans, Gunna, Scheffer, Parikh, Mahadik (BIB32) 2002; 58 Aebi (BIB3) 1984; 3 Stoklasova, Petrakova, Michalickova, Zapletalek (BIB66) 1990; 33 Kirkpatrick, Buchanan, Breier, Carpenter (BIB33) 1993; 47 Mahadik, Mukherjee, Horrobin, Jenkins, Correnti, Scheffer (BIB45) 1996; 63 Mukherjee, Mahadik, Scheffer, Correnti, Kelkar (BIB52) 1996; 19 Christensen, Christensen (BIB14) 1988; 78 Cadet, Perumal (BIB12) 1990; 28 Peet, Laugharne, Rangarajan, Reynolds (BIB59) 1993; 8 Akyol, Herken, Uz, Fadillioglu, Unal, Sogut, Ozyurt, Savas (BIB4) 2002; 26 Jablensky, Sartorius, Ernberg, Anker, Korten, Cooper, Day, Bertelsen (BIB27) 1991; 20 Gershon, DeLisi, Hamovit, Nurnberg, Maxwell, Schreiber, Dauphinais, Dingman, Guroff (BIB21) 1988; 45 Mahadik, Evans (BIB40) 1997; 33 Maier, Lichtermann, Minges, Hallmayer, Heun, Benkert, Levinson (BIB50) 1993; 50 Simopoulos (BIB64) 1991; 54 Kraepelin, E., 1899. Psychiatrie. Ein Lehrbuch fur Studierende und Arzte, 6th ed. Johann Ambrocius Barth, Leipzig Maes, Chritophe, Delanghe, Altamura, Neels, Meltzer (BIB39) 1999; 85 Nemets, Stahl, Belmaker (BIB53) 2002; 159 Williams (BIB71) 1988; 45 Crow (BIB17) 1995 Edwards, R.W., Peet, M., 1999. Essential fatty acid intake in relation to depression. In: Peet, M., Glen, I., Horrobin, D.F. (Eds.), Phospholipid Spectrum Disorders in Psychiatry. Marius Press, Lancashire, UK Overall, Gorham (BIB55) 1962; 10 Yao, Reddy, van Kammen (BIB74) 2001; 15 Reddy, Mahadik, Mukherjee, Murthy (BIB61) 1991; 30 Mahadik, Mulchandani, Hegde, Ranjekar (BIB48) 1999 Mahadik, Scheffer (BIB44) 1996; 55 Smythies (BIB65) 1997; 24 Yao, Leonard, Reddy (BIB73) 2000; 42 Abdalla, Monteiro, Oliveira, Bechara (BIB1) 1986; 32 Horrobin, Glen, Vaddadi (BIB23) 1994; 13 Kuloglu, Ustundag, Atmaca, Canatan, Tezcan, Clinkilinc (BIB35) 2002; 20 Ohkawa, Ohishi, Yagi (BIB54) 1979; 95 Carpenter, Heinrichs, Wagman (BIB13) 1988; 145 Yao, Reddy, McElhinny, van Kammen (BIB72) 1998; 32 Mahadik, Evans, Lal (BIB41) 2001; 25 Jeding, Evans, Akanmu, Dexter, Spencer, Aruoma, Jenner, Halliwell (BIB28) 1995; 49 Crow (BIB16) 1990; 156 Mahadik, Sitasawad, Mulchandani (BIB49) 1999 Kay, Fiszbein, Opler (BIB30) 1987; 13 Mahadik, Shendarkar, Scheffer, Mukherjee, Correnti (BIB46) 1996; 55 Cadet, Lohr (BIB11) 1987; 5 Stoll, Severus, Freeman, Rueter, Zboyan, Diamond, Cress, Marangell (BIB67) 1999; 56 Horrobin (BIB24) 1998; 30 Lohr, Underhill, Moir, Jeste (BIB38) 1990; 28 Angst (BIB7) 2002; 57 Reddy, Yao (BIB62) 1996; 55 Leff, Sartorius, Jablensky, Korten, Ernberg (BIB36) 1992; 22 Peet, M., Glen, I., Horrobin, D.F. (Eds), 1999. Phospholipid Spectrum Disorders in Psychiatry. Marius Press Lancashire, UK Arvindakshan, Ghate, Ranjekar, Evans, Mahadik (BIB9) 2003; 62 Jablensky (BIB25) 1986; 12 Mahadik, Gowda (BIB42) 1996; 32 Taylor (BIB69) 1992; 149 Kirkpatrick (10.1016/S0165-1781(03)00220-8_BIB33) 1993; 47 10.1016/S0165-1781(03)00220-8_BIB58 Cadet (10.1016/S0165-1781(03)00220-8_BIB11) 1987; 5 Mahadik (10.1016/S0165-1781(03)00220-8_BIB46) 1996; 55 Peet (10.1016/S0165-1781(03)00220-8_BIB57) 2002; 36 10.1016/S0165-1781(03)00220-8_BIB19 10.1016/S0165-1781(03)00220-8_BIB18 Taylor (10.1016/S0165-1781(03)00220-8_BIB69) 1992; 149 Jablensky (10.1016/S0165-1781(03)00220-8_BIB26) 1986; 40 Aebi (10.1016/S0165-1781(03)00220-8_BIB3) 1984; 3 McCreadie (10.1016/S0165-1781(03)00220-8_BIB51) 1995; 170 Reddy (10.1016/S0165-1781(03)00220-8_BIB61) 1991; 30 Khan (10.1016/S0165-1781(03)00220-8_BIB31) 2001; 158 Mukherjee (10.1016/S0165-1781(03)00220-8_BIB52) 1996; 19 Ohkawa (10.1016/S0165-1781(03)00220-8_BIB54) 1979; 95 Andreasen (10.1016/S0165-1781(03)00220-8_BIB6) 1982; 39 Mahadik (10.1016/S0165-1781(03)00220-8_BIB43) 1996; 19 Yao (10.1016/S0165-1781(03)00220-8_BIB74) 2001; 15 Lohr (10.1016/S0165-1781(03)00220-8_BIB37) 1988; 14 Khan (10.1016/S0165-1781(03)00220-8_BIB32) 2002; 58 Parikh (10.1016/S0165-1781(03)00220-8_BIB56) 2002; 37 Yao (10.1016/S0165-1781(03)00220-8_BIB72) 1998; 32 Stoklasova (10.1016/S0165-1781(03)00220-8_BIB66) 1990; 33 Adler (10.1016/S0165-1781(03)00220-8_BIB2) 1993; 150 Fenton (10.1016/S0165-1781(03)00220-8_BIB20) 2000; 47 Christensen (10.1016/S0165-1781(03)00220-8_BIB14) 1988; 78 Mahadik (10.1016/S0165-1781(03)00220-8_BIB41) 2001; 25 Peet (10.1016/S0165-1781(03)00220-8_BIB59) 1993; 8 Mahadik (10.1016/S0165-1781(03)00220-8_BIB40) 1997; 33 Crow (10.1016/S0165-1781(03)00220-8_BIB17) 1995 Kuloglu (10.1016/S0165-1781(03)00220-8_BIB35) 2002; 20 Kay (10.1016/S0165-1781(03)00220-8_BIB30) 1987; 13 Maes (10.1016/S0165-1781(03)00220-8_BIB39) 1999; 85 Mahadik (10.1016/S0165-1781(03)00220-8_BIB45) 1996; 63 10.1016/S0165-1781(03)00220-8_BIB34 Simopoulos (10.1016/S0165-1781(03)00220-8_BIB64) 1991; 54 Mahadik (10.1016/S0165-1781(03)00220-8_BIB48) 1999 Cadet (10.1016/S0165-1781(03)00220-8_BIB12) 1990; 28 Arvindakshan (10.1016/S0165-1781(03)00220-8_BIB10) 2003; 53 Abdalla (10.1016/S0165-1781(03)00220-8_BIB1) 1986; 32 Carpenter (10.1016/S0165-1781(03)00220-8_BIB13) 1988; 145 Maier (10.1016/S0165-1781(03)00220-8_BIB50) 1993; 50 Horrobin (10.1016/S0165-1781(03)00220-8_BIB24) 1998; 30 Jablensky (10.1016/S0165-1781(03)00220-8_BIB27) 1991; 20 Crow (10.1016/S0165-1781(03)00220-8_BIB16) 1990; 156 Reddy (10.1016/S0165-1781(03)00220-8_BIB62) 1996; 55 Overall (10.1016/S0165-1781(03)00220-8_BIB55) 1962; 10 Akyol (10.1016/S0165-1781(03)00220-8_BIB4) 2002; 26 Roy (10.1016/S0165-1781(03)00220-8_BIB63) 1984; 42 Wainwright (10.1016/S0165-1781(03)00220-8_BIB70) 1992; 16 Jablensky (10.1016/S0165-1781(03)00220-8_BIB25) 1986; 12 Nemets (10.1016/S0165-1781(03)00220-8_BIB53) 2002; 159 Arvindakshan (10.1016/S0165-1781(03)00220-8_BIB9) 2003; 62 Stoll (10.1016/S0165-1781(03)00220-8_BIB67) 1999; 56 Leff (10.1016/S0165-1781(03)00220-8_BIB36) 1992; 22 10.1016/S0165-1781(03)00220-8_BIB8 Subramanyam (10.1016/S0165-1781(03)00220-8_BIB68) 1991; 181 Gershon (10.1016/S0165-1781(03)00220-8_BIB21) 1988; 45 Horrobin (10.1016/S0165-1781(03)00220-8_BIB23) 1994; 13 Mahadik (10.1016/S0165-1781(03)00220-8_BIB47) 1998; 43 10.1016/S0165-1781(03)00220-8_BIB29 Mahadik (10.1016/S0165-1781(03)00220-8_BIB49) 1999 Ramchand (10.1016/S0165-1781(03)00220-8_BIB60) 1996; 55 Mahadik (10.1016/S0165-1781(03)00220-8_BIB42) 1996; 32 Lohr (10.1016/S0165-1781(03)00220-8_BIB38) 1990; 28 Smythies (10.1016/S0165-1781(03)00220-8_BIB65) 1997; 24 Mahadik (10.1016/S0165-1781(03)00220-8_BIB44) 1996; 55 Yao (10.1016/S0165-1781(03)00220-8_BIB73) 2000; 42 Jeding (10.1016/S0165-1781(03)00220-8_BIB28) 1995; 49 Williams (10.1016/S0165-1781(03)00220-8_BIB71) 1988; 45 (10.1016/S0165-1781(03)00220-8_BIB5) 1994 Crow (10.1016/S0165-1781(03)00220-8_BIB15) 1985; 11 Glen (10.1016/S0165-1781(03)00220-8_BIB22) 1994; 12 Angst (10.1016/S0165-1781(03)00220-8_BIB7) 2002; 57 |
References_xml | – volume: 43 start-page: 674 year: 1998 end-page: 679 ident: BIB47 article-title: Elevated plasma lipid peroxides at the onset of non-affective psychosis publication-title: Biological Psychiatry – reference: Peet, M., Glen, I., Horrobin, D.F. (Eds), 1999. Phospholipid Spectrum Disorders in Psychiatry. Marius Press Lancashire, UK – volume: 62 start-page: 195 year: 2003 end-page: 204 ident: BIB9 article-title: Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia publication-title: Schizophrenia Research – volume: 45 start-page: 742 year: 1988 end-page: 747 ident: BIB71 article-title: A structured interview guide for the Hamilton Depression Rating Scale publication-title: Archives of General Psychiatry – volume: 145 start-page: 578 year: 1988 end-page: 583 ident: BIB13 article-title: Deficit and non-deficit forms of schizophrenia: the concept publication-title: American Journal of Psychiatry – volume: 39 start-page: 789 year: 1982 end-page: 794 ident: BIB6 article-title: Negative vs. positive schizophrenia: definition and validation publication-title: Archives of General Psychiatry – volume: 56 start-page: 407 year: 1999 end-page: 412 ident: BIB67 article-title: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial publication-title: Archives of General Psychiatry – volume: 19 start-page: 19 year: 1996 end-page: 26 ident: BIB52 article-title: Impaired antioxidant defense at the onset of psychosis publication-title: Schizophrenia Research – volume: 20 start-page: 1 year: 1991 end-page: 97 ident: BIB27 article-title: Schizophrenia: manifestations, incidence and course in different cultures publication-title: Psychological Medicine and Monographs Supplement – volume: 28 start-page: 535 year: 1990 end-page: 539 ident: BIB38 article-title: Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia publication-title: Biological Psychiatry – volume: 78 start-page: 587 year: 1988 end-page: 591 ident: BIB14 article-title: Fat consumption and schizophrenia publication-title: Acta Psychiatrica Scandinavica – volume: 156 start-page: 788 year: 1990 end-page: 797 ident: BIB16 article-title: The continuum of psychosis and its genetic origins: the sixty-fifth Maudsley Lecture publication-title: British Journal of Psychiatry – volume: 159 start-page: 477 year: 2002 end-page: 479 ident: BIB53 article-title: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder publication-title: American Journal of Psychiatry – start-page: 167 year: 1999 end-page: 179 ident: BIB48 article-title: Cultural and socio–economic differences in dietary intake of essential fatty acids and antioxidants: effects on the course and outcome of schizophrenia publication-title: Phospholipid Spectrum Disorders in Psychiatry – volume: 16 start-page: 193 year: 1992 end-page: 205 ident: BIB70 article-title: Do essential fatty acids play a role in brain and behavioral development? publication-title: Neuroscience and Biobehavioral Reviews – volume: 33 start-page: 5 year: 1997 end-page: 17 ident: BIB40 article-title: Essential fatty acids in the treatment of schizophrenia publication-title: Drugs of Today – volume: 37 start-page: 43 year: 2002 end-page: 51 ident: BIB56 article-title: Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain publication-title: Journal of Psychiatric Research – volume: 13 start-page: 195 year: 1994 end-page: 207 ident: BIB23 article-title: The membrane hypothesis of schizophrenia publication-title: Schizophrenia Research – reference: Edwards, R.W., Peet, M., 1999. Essential fatty acid intake in relation to depression. In: Peet, M., Glen, I., Horrobin, D.F. (Eds.), Phospholipid Spectrum Disorders in Psychiatry. Marius Press, Lancashire, UK – volume: 11 start-page: 471 year: 1985 end-page: 486 ident: BIB15 article-title: The two-syndrome concept: origins and current status publication-title: Schizophrenia Bulletin – volume: 95 start-page: 351 year: 1979 end-page: 358 ident: BIB54 article-title: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction publication-title: Analytical Biochemistry – volume: 49 start-page: 359 year: 1995 end-page: 365 ident: BIB28 article-title: Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs publication-title: Biochemical Pharmacology – volume: 57 start-page: 5 year: 2002 end-page: 13 ident: BIB7 article-title: Historical aspects of the dichotomy between manic-depressive disorders and schizophrenia publication-title: Schizophrenia Research – reference: Evans, D.R., Parikh, V.V., Khan, M.M., Coussons, C., Buckley, P.F., Mahadik, S.P., 2003. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids, in press – volume: 22 start-page: 131 year: 1992 end-page: 145 ident: BIB36 article-title: The International Pilot Study of Schizophrenia: five-year follow-up findings publication-title: Psychological Medicine – volume: 42 start-page: 628 year: 1984 end-page: 633 ident: BIB63 article-title: Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain publication-title: Journal of Neurochemistry – volume: 12 start-page: 53 year: 1994 end-page: 61 ident: BIB22 article-title: A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases publication-title: Schizophrenia Research – volume: 20 start-page: 171 year: 2002 end-page: 175 ident: BIB35 article-title: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder publication-title: Cell Biochemistry and Function – start-page: 99 year: 1999 end-page: 111 ident: BIB49 article-title: Membrane peroxidation and the neuropathology of schizophrenia publication-title: Phospholipid Spectrum Disorders in Psychiatry – volume: 25 start-page: 463 year: 2001 end-page: 493 ident: BIB41 article-title: Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia publication-title: Progress in Neuropsychopharmacology and Biological Psychiatry – volume: 45 start-page: 328 year: 1988 end-page: 336 ident: BIB21 article-title: A controlled family study of chronic psychosis publication-title: Archives of General Psychiatry – reference: Kraepelin, E., 1899. Psychiatrie. Ein Lehrbuch fur Studierende und Arzte, 6th ed. Johann Ambrocius Barth, Leipzig – volume: 181 start-page: 573 year: 1991 end-page: 578 ident: BIB68 article-title: Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol publication-title: Biochemical and Biophysical Research Communications – volume: 13 start-page: 261 year: 1987 end-page: 276 ident: BIB30 article-title: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia publication-title: Schizophrenia Bulletin – volume: 32 start-page: 385 year: 1998 end-page: 391 ident: BIB72 article-title: Effects of haloperidol on antioxidant defense system enzymes in schizophrenia publication-title: Journal of Psychiatric Research – volume: 54 start-page: 438 year: 1991 end-page: 463 ident: BIB64 article-title: Omega-3 fatty acids in health and disease and in growth and development publication-title: American Journal of Clinical Nutrition – volume: 24 start-page: 357 year: 1997 end-page: 364 ident: BIB65 article-title: Oxidative reactions and schizophrenia: a review-discussion publication-title: Schizophrenia Research – volume: 53 start-page: 56 year: 2003 end-page: 64 ident: BIB10 article-title: Membrane essential polyunsaturated fatty acids (EPUFA) and schizophrenia outcome: EPUFA and lipid peroxide levels in never-medicated and medicated schizophrenics publication-title: Biological Psychiatry – volume: 85 start-page: 275 year: 1999 end-page: 291 ident: BIB39 article-title: Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients publication-title: Psychiatric Research – reference: Kahlbaum, K., 1963. Die Gruppirung der Psychischen Krankheiten und die Eintheilung der Seelenstorungen. AW Kafemann, Danzing – volume: 149 start-page: 22 year: 1992 end-page: 32 ident: BIB69 article-title: Are schizophrenia and affective disorder related? A selective literature review publication-title: American Journal of Psychiatry – volume: 55 start-page: 33 year: 1996 end-page: 43 ident: BIB62 article-title: Free radical pathology in schizophrenia: a review publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids – volume: 14 start-page: 291 year: 1988 end-page: 296 ident: BIB37 article-title: Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms publication-title: Schizophrenia Bulletin – volume: 32 start-page: 553 year: 1996 end-page: 565 ident: BIB42 article-title: Antioxidants in the treatment of schizophrenia publication-title: Drugs of Today – volume: 30 start-page: 193 year: 1998 end-page: 208 ident: BIB24 article-title: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia publication-title: Schizophrenia Research – volume: 55 start-page: 65 year: 1996 end-page: 70 ident: BIB46 article-title: Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids – volume: 40 start-page: 1 year: 1986 end-page: 163 ident: BIB26 article-title: Schizophrenia and social adjustment. A prospective longitudinal study publication-title: Monogr Gesamtgeb Psychiatr Psychiatry Series – volume: 170 start-page: 1 year: 1995 end-page: 8 ident: BIB51 article-title: The Nithsdale Schizophrenia Surveys XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and in normal subjects publication-title: British Journal of Psychiatry – volume: 3 start-page: 277 year: 1984 end-page: 281 ident: BIB3 article-title: Catalase in vitro publication-title: Methods of Enzymatic Analysis – volume: 28 start-page: 738 year: 1990 end-page: 740 ident: BIB12 article-title: Chronic treatment with prolixin causes oxidative stress in rat brain publication-title: Biological Psychiatry – start-page: 151 year: 1995 end-page: 163 ident: BIB17 article-title: Psychotic continuum or disease entities? The critical impact of nosology on the problem of etiology publication-title: Psychotic Continuum – volume: 19 start-page: 1 year: 1996 end-page: 17 ident: BIB43 article-title: Free radical pathology and antioxidant defense in schizophrenia: a review publication-title: Schizophrenia Research – volume: 47 start-page: 47 year: 1993 end-page: 56 ident: BIB33 article-title: Case identification and stability of the deficit syndrome of schizophrenia publication-title: Psychiatry Research – volume: 55 start-page: 45 year: 1996 end-page: 54 ident: BIB44 article-title: Oxidative injury and potential use of antioxidants in schizophrenia publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids – volume: 158 start-page: 1449 year: 2001 end-page: 1454 ident: BIB31 article-title: Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database publication-title: American Journal of Psychiatry – volume: 55 start-page: 27 year: 1996 end-page: 31 ident: BIB60 article-title: Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids – volume: 12 start-page: 52 year: 1986 end-page: 73 ident: BIB25 article-title: Epidemiology of schizophrenia: a European perspective publication-title: Schizophrenia Bulletin – volume: 58 start-page: 1 year: 2002 end-page: 10 ident: BIB32 article-title: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics publication-title: Schizophrenia Research – volume: 10 start-page: 799 year: 1962 end-page: 812 ident: BIB55 article-title: Brief Psychiatric Rating Scale publication-title: Psychological Reports – volume: 36 start-page: 7 year: 2002 end-page: 18 ident: BIB57 article-title: A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms publication-title: Journal of Psychiatric Research – volume: 47 start-page: 8 year: 2000 end-page: 21 ident: BIB20 article-title: Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia publication-title: Biological Psychiatry – volume: 50 start-page: 871 year: 1993 end-page: 883 ident: BIB50 article-title: Continuity and discontinuity of affective disorders and schizophrenia: results of a controlled family study publication-title: Archives of General Psychiatry – volume: 33 start-page: 501 year: 1990 end-page: 505 ident: BIB66 article-title: Activities of blood glutathione peroxidase in schizophrenic and depressive patients publication-title: Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove – year: 1994 ident: BIB5 publication-title: Diagnostic and Statistical Manual of Mental Disorders – volume: 30 start-page: 409 year: 1991 end-page: 412 ident: BIB61 article-title: Enzymes of the antioxidant defense system in chronic schizophrenic patients publication-title: Biological Psychiatry – reference: Arvindakshan, M., 2003. Ph.D. Thesis: The Role of Membrane Essential Polyunsaturated Fatty Acids in Schizophrenia Outcome. Pune University Press, Pune, India – volume: 26 start-page: 995 year: 2002 end-page: 1005 ident: BIB4 article-title: The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the role of oxidant/antioxidant imbalance publication-title: Progress in Neuro-Psychopharmacology and Biological Psychiatry – volume: 150 start-page: 1405 year: 1993 end-page: 1407 ident: BIB2 article-title: Vitamin E treatment of tardive dyskinesia publication-title: American Journal of Psychiatry – volume: 42 start-page: 7 year: 2000 end-page: 17 ident: BIB73 article-title: Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients publication-title: Schizophrenia Research – volume: 5 start-page: 40 year: 1987 end-page: 48 ident: BIB11 article-title: Free radicals and the developmental pathophysiology of schizophrenic burnout publication-title: Integrative Psychiatry – volume: 63 start-page: 133 year: 1996 end-page: 142 ident: BIB45 article-title: Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal controls publication-title: Psychiatry Research – volume: 8 start-page: 151 year: 1993 end-page: 153 ident: BIB59 article-title: Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment publication-title: International Clinical Psychopharmacology – volume: 32 start-page: 805 year: 1986 end-page: 807 ident: BIB1 article-title: Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients publication-title: Clinical Chemistry – volume: 15 start-page: 287 year: 2001 end-page: 310 ident: BIB74 article-title: Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications publication-title: CNS Drugs – volume: 24 start-page: 357 issue: 3 year: 1997 ident: 10.1016/S0165-1781(03)00220-8_BIB65 article-title: Oxidative reactions and schizophrenia: a review-discussion publication-title: Schizophrenia Research doi: 10.1016/S0920-9964(97)00005-4 – ident: 10.1016/S0165-1781(03)00220-8_BIB29 – volume: 58 start-page: 1 year: 2002 ident: 10.1016/S0165-1781(03)00220-8_BIB32 article-title: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics publication-title: Schizophrenia Research doi: 10.1016/S0920-9964(01)00334-6 – volume: 20 start-page: 1 year: 1991 ident: 10.1016/S0165-1781(03)00220-8_BIB27 article-title: Schizophrenia: manifestations, incidence and course in different cultures publication-title: Psychological Medicine and Monographs Supplement doi: 10.1017/S0264180100000904 – volume: 10 start-page: 799 year: 1962 ident: 10.1016/S0165-1781(03)00220-8_BIB55 article-title: Brief Psychiatric Rating Scale publication-title: Psychological Reports doi: 10.2466/pr0.1962.10.3.799 – volume: 150 start-page: 1405 year: 1993 ident: 10.1016/S0165-1781(03)00220-8_BIB2 article-title: Vitamin E treatment of tardive dyskinesia publication-title: American Journal of Psychiatry doi: 10.1176/ajp.150.9.1405 – volume: 33 start-page: 501 issue: 5 year: 1990 ident: 10.1016/S0165-1781(03)00220-8_BIB66 article-title: Activities of blood glutathione peroxidase in schizophrenic and depressive patients publication-title: Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove – volume: 56 start-page: 407 issue: 5 year: 1999 ident: 10.1016/S0165-1781(03)00220-8_BIB67 article-title: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial publication-title: Archives of General Psychiatry doi: 10.1001/archpsyc.56.5.407 – volume: 95 start-page: 351 issue: 2 year: 1979 ident: 10.1016/S0165-1781(03)00220-8_BIB54 article-title: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction publication-title: Analytical Biochemistry doi: 10.1016/0003-2697(79)90738-3 – volume: 45 start-page: 742 year: 1988 ident: 10.1016/S0165-1781(03)00220-8_BIB71 article-title: A structured interview guide for the Hamilton Depression Rating Scale publication-title: Archives of General Psychiatry doi: 10.1001/archpsyc.1988.01800320058007 – volume: 37 start-page: 43 year: 2002 ident: 10.1016/S0165-1781(03)00220-8_BIB56 article-title: Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain publication-title: Journal of Psychiatric Research doi: 10.1016/S0022-3956(02)00048-1 – volume: 40 start-page: 1 year: 1986 ident: 10.1016/S0165-1781(03)00220-8_BIB26 article-title: Schizophrenia and social adjustment. A prospective longitudinal study publication-title: Monogr Gesamtgeb Psychiatr Psychiatry Series – volume: 36 start-page: 7 year: 2002 ident: 10.1016/S0165-1781(03)00220-8_BIB57 article-title: A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms publication-title: Journal of Psychiatric Research doi: 10.1016/S0022-3956(01)00048-6 – volume: 63 start-page: 133 issue: 2–3 year: 1996 ident: 10.1016/S0165-1781(03)00220-8_BIB45 article-title: Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal controls publication-title: Psychiatry Research doi: 10.1016/0165-1781(96)02899-5 – volume: 32 start-page: 805 issue: 5 year: 1986 ident: 10.1016/S0165-1781(03)00220-8_BIB1 article-title: Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients publication-title: Clinical Chemistry doi: 10.1093/clinchem/32.5.805 – volume: 85 start-page: 275 year: 1999 ident: 10.1016/S0165-1781(03)00220-8_BIB39 article-title: Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients publication-title: Psychiatric Research doi: 10.1016/S0165-1781(99)00014-1 – ident: 10.1016/S0165-1781(03)00220-8_BIB58 – volume: 5 start-page: 40 year: 1987 ident: 10.1016/S0165-1781(03)00220-8_BIB11 article-title: Free radicals and the developmental pathophysiology of schizophrenic burnout publication-title: Integrative Psychiatry – volume: 149 start-page: 22 year: 1992 ident: 10.1016/S0165-1781(03)00220-8_BIB69 article-title: Are schizophrenia and affective disorder related? A selective literature review publication-title: American Journal of Psychiatry doi: 10.1176/ajp.149.1.22 – volume: 54 start-page: 438 issue: 3 year: 1991 ident: 10.1016/S0165-1781(03)00220-8_BIB64 article-title: Omega-3 fatty acids in health and disease and in growth and development publication-title: American Journal of Clinical Nutrition doi: 10.1093/ajcn/54.3.438 – ident: 10.1016/S0165-1781(03)00220-8_BIB8 – volume: 16 start-page: 193 year: 1992 ident: 10.1016/S0165-1781(03)00220-8_BIB70 article-title: Do essential fatty acids play a role in brain and behavioral development? publication-title: Neuroscience and Biobehavioral Reviews doi: 10.1016/S0149-7634(05)80180-0 – volume: 159 start-page: 477 issue: 3 year: 2002 ident: 10.1016/S0165-1781(03)00220-8_BIB53 article-title: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder publication-title: American Journal of Psychiatry doi: 10.1176/appi.ajp.159.3.477 – volume: 42 start-page: 628 issue: 3 year: 1984 ident: 10.1016/S0165-1781(03)00220-8_BIB63 article-title: Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain publication-title: Journal of Neurochemistry doi: 10.1111/j.1471-4159.1984.tb02728.x – volume: 32 start-page: 553 year: 1996 ident: 10.1016/S0165-1781(03)00220-8_BIB42 article-title: Antioxidants in the treatment of schizophrenia publication-title: Drugs of Today – ident: 10.1016/S0165-1781(03)00220-8_BIB34 – volume: 181 start-page: 573 issue: 2 year: 1991 ident: 10.1016/S0165-1781(03)00220-8_BIB68 article-title: Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol publication-title: Biochemical and Biophysical Research Communications doi: 10.1016/0006-291X(91)91228-5 – volume: 22 start-page: 131 issue: 1 year: 1992 ident: 10.1016/S0165-1781(03)00220-8_BIB36 article-title: The International Pilot Study of Schizophrenia: five-year follow-up findings publication-title: Psychological Medicine doi: 10.1017/S0033291700032797 – volume: 3 start-page: 277 year: 1984 ident: 10.1016/S0165-1781(03)00220-8_BIB3 article-title: Catalase in vitro – volume: 11 start-page: 471 year: 1985 ident: 10.1016/S0165-1781(03)00220-8_BIB15 article-title: The two-syndrome concept: origins and current status publication-title: Schizophrenia Bulletin doi: 10.1093/schbul/11.3.471 – volume: 12 start-page: 52 issue: 1 year: 1986 ident: 10.1016/S0165-1781(03)00220-8_BIB25 article-title: Epidemiology of schizophrenia: a European perspective publication-title: Schizophrenia Bulletin doi: 10.1093/schbul/12.1.52 – volume: 30 start-page: 193 issue: 3 year: 1998 ident: 10.1016/S0165-1781(03)00220-8_BIB24 article-title: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia publication-title: Schizophrenia Research doi: 10.1016/S0920-9964(97)00151-5 – volume: 12 start-page: 53 year: 1994 ident: 10.1016/S0165-1781(03)00220-8_BIB22 article-title: A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases publication-title: Schizophrenia Research doi: 10.1016/0920-9964(94)90084-1 – volume: 30 start-page: 409 issue: 4 year: 1991 ident: 10.1016/S0165-1781(03)00220-8_BIB61 article-title: Enzymes of the antioxidant defense system in chronic schizophrenic patients publication-title: Biological Psychiatry doi: 10.1016/0006-3223(91)90298-Z – volume: 15 start-page: 287 issue: 4 year: 2001 ident: 10.1016/S0165-1781(03)00220-8_BIB74 article-title: Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications publication-title: CNS Drugs doi: 10.2165/00023210-200115040-00004 – volume: 20 start-page: 171 issue: 2 year: 2002 ident: 10.1016/S0165-1781(03)00220-8_BIB35 article-title: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder publication-title: Cell Biochemistry and Function doi: 10.1002/cbf.940 – volume: 26 start-page: 995 year: 2002 ident: 10.1016/S0165-1781(03)00220-8_BIB4 article-title: The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the role of oxidant/antioxidant imbalance publication-title: Progress in Neuro-Psychopharmacology and Biological Psychiatry doi: 10.1016/S0278-5846(02)00220-8 – volume: 42 start-page: 7 issue: 1 year: 2000 ident: 10.1016/S0165-1781(03)00220-8_BIB73 article-title: Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients publication-title: Schizophrenia Research doi: 10.1016/S0920-9964(99)00095-X – volume: 47 start-page: 8 year: 2000 ident: 10.1016/S0165-1781(03)00220-8_BIB20 article-title: Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia publication-title: Biological Psychiatry doi: 10.1016/S0006-3223(99)00092-X – volume: 78 start-page: 587 year: 1988 ident: 10.1016/S0165-1781(03)00220-8_BIB14 article-title: Fat consumption and schizophrenia publication-title: Acta Psychiatrica Scandinavica doi: 10.1111/j.1600-0447.1988.tb06388.x – volume: 53 start-page: 56 year: 2003 ident: 10.1016/S0165-1781(03)00220-8_BIB10 article-title: Membrane essential polyunsaturated fatty acids (EPUFA) and schizophrenia outcome: EPUFA and lipid peroxide levels in never-medicated and medicated schizophrenics publication-title: Biological Psychiatry doi: 10.1016/S0006-3223(02)01443-9 – volume: 62 start-page: 195 year: 2003 ident: 10.1016/S0165-1781(03)00220-8_BIB9 article-title: Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia publication-title: Schizophrenia Research doi: 10.1016/S0920-9964(02)00284-0 – volume: 55 start-page: 65 year: 1996 ident: 10.1016/S0165-1781(03)00220-8_BIB46 article-title: Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids doi: 10.1016/S0952-3278(96)90147-7 – volume: 170 start-page: 1 year: 1995 ident: 10.1016/S0165-1781(03)00220-8_BIB51 article-title: The Nithsdale Schizophrenia Surveys XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and in normal subjects publication-title: British Journal of Psychiatry – volume: 39 start-page: 789 year: 1982 ident: 10.1016/S0165-1781(03)00220-8_BIB6 article-title: Negative vs. positive schizophrenia: definition and validation publication-title: Archives of General Psychiatry doi: 10.1001/archpsyc.1982.04290070025006 – volume: 13 start-page: 195 issue: 3 year: 1994 ident: 10.1016/S0165-1781(03)00220-8_BIB23 article-title: The membrane hypothesis of schizophrenia publication-title: Schizophrenia Research doi: 10.1016/0920-9964(94)90043-4 – volume: 145 start-page: 578 year: 1988 ident: 10.1016/S0165-1781(03)00220-8_BIB13 article-title: Deficit and non-deficit forms of schizophrenia: the concept publication-title: American Journal of Psychiatry doi: 10.1176/ajp.145.5.578 – ident: 10.1016/S0165-1781(03)00220-8_BIB19 doi: 10.1016/j.plefa.2003.08.010 – volume: 156 start-page: 788 year: 1990 ident: 10.1016/S0165-1781(03)00220-8_BIB16 article-title: The continuum of psychosis and its genetic origins: the sixty-fifth Maudsley Lecture publication-title: British Journal of Psychiatry doi: 10.1192/bjp.156.6.788 – volume: 33 start-page: 5 year: 1997 ident: 10.1016/S0165-1781(03)00220-8_BIB40 article-title: Essential fatty acids in the treatment of schizophrenia publication-title: Drugs of Today – ident: 10.1016/S0165-1781(03)00220-8_BIB18 – volume: 19 start-page: 19 issue: 1 year: 1996 ident: 10.1016/S0165-1781(03)00220-8_BIB52 article-title: Impaired antioxidant defense at the onset of psychosis publication-title: Schizophrenia Research doi: 10.1016/0920-9964(95)00048-8 – volume: 45 start-page: 328 year: 1988 ident: 10.1016/S0165-1781(03)00220-8_BIB21 article-title: A controlled family study of chronic psychosis publication-title: Archives of General Psychiatry doi: 10.1001/archpsyc.1988.01800280038006 – volume: 25 start-page: 463 issue: 3 year: 2001 ident: 10.1016/S0165-1781(03)00220-8_BIB41 article-title: Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia publication-title: Progress in Neuropsychopharmacology and Biological Psychiatry doi: 10.1016/S0278-5846(00)00181-0 – volume: 49 start-page: 359 issue: 3 year: 1995 ident: 10.1016/S0165-1781(03)00220-8_BIB28 article-title: Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs publication-title: Biochemical Pharmacology doi: 10.1016/0006-2952(94)00424-K – volume: 55 start-page: 27 issue: 1–2 year: 1996 ident: 10.1016/S0165-1781(03)00220-8_BIB60 article-title: Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids doi: 10.1016/S0952-3278(96)90142-8 – start-page: 99 year: 1999 ident: 10.1016/S0165-1781(03)00220-8_BIB49 article-title: Membrane peroxidation and the neuropathology of schizophrenia – volume: 158 start-page: 1449 year: 2001 ident: 10.1016/S0165-1781(03)00220-8_BIB31 article-title: Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database publication-title: American Journal of Psychiatry doi: 10.1176/appi.ajp.158.9.1449 – start-page: 151 year: 1995 ident: 10.1016/S0165-1781(03)00220-8_BIB17 article-title: Psychotic continuum or disease entities? The critical impact of nosology on the problem of etiology – volume: 32 start-page: 385 issue: 6 year: 1998 ident: 10.1016/S0165-1781(03)00220-8_BIB72 article-title: Effects of haloperidol on antioxidant defense system enzymes in schizophrenia publication-title: Journal of Psychiatric Research doi: 10.1016/S0022-3956(98)00028-4 – start-page: 167 year: 1999 ident: 10.1016/S0165-1781(03)00220-8_BIB48 article-title: Cultural and socio–economic differences in dietary intake of essential fatty acids and antioxidants: effects on the course and outcome of schizophrenia – volume: 50 start-page: 871 year: 1993 ident: 10.1016/S0165-1781(03)00220-8_BIB50 article-title: Continuity and discontinuity of affective disorders and schizophrenia: results of a controlled family study publication-title: Archives of General Psychiatry doi: 10.1001/archpsyc.1993.01820230041004 – volume: 55 start-page: 33 issue: 1–2 year: 1996 ident: 10.1016/S0165-1781(03)00220-8_BIB62 article-title: Free radical pathology in schizophrenia: a review publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids doi: 10.1016/S0952-3278(96)90143-X – volume: 28 start-page: 738 issue: 8 year: 1990 ident: 10.1016/S0165-1781(03)00220-8_BIB12 article-title: Chronic treatment with prolixin causes oxidative stress in rat brain publication-title: Biological Psychiatry doi: 10.1016/0006-3223(90)90461-A – volume: 14 start-page: 291 year: 1988 ident: 10.1016/S0165-1781(03)00220-8_BIB37 article-title: Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms publication-title: Schizophrenia Bulletin doi: 10.1093/schbul/14.2.291 – volume: 19 start-page: 1 issue: 1 year: 1996 ident: 10.1016/S0165-1781(03)00220-8_BIB43 article-title: Free radical pathology and antioxidant defense in schizophrenia: a review publication-title: Schizophrenia Research doi: 10.1016/0920-9964(95)00049-6 – volume: 57 start-page: 5 year: 2002 ident: 10.1016/S0165-1781(03)00220-8_BIB7 article-title: Historical aspects of the dichotomy between manic-depressive disorders and schizophrenia publication-title: Schizophrenia Research doi: 10.1016/S0920-9964(02)00328-6 – volume: 47 start-page: 47 year: 1993 ident: 10.1016/S0165-1781(03)00220-8_BIB33 article-title: Case identification and stability of the deficit syndrome of schizophrenia publication-title: Psychiatry Research doi: 10.1016/0165-1781(93)90054-K – volume: 55 start-page: 45 year: 1996 ident: 10.1016/S0165-1781(03)00220-8_BIB44 article-title: Oxidative injury and potential use of antioxidants in schizophrenia publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids doi: 10.1016/S0952-3278(96)90144-1 – volume: 28 start-page: 535 year: 1990 ident: 10.1016/S0165-1781(03)00220-8_BIB38 article-title: Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia publication-title: Biological Psychiatry doi: 10.1016/0006-3223(90)90490-S – year: 1994 ident: 10.1016/S0165-1781(03)00220-8_BIB5 – volume: 43 start-page: 674 issue: 9 year: 1998 ident: 10.1016/S0165-1781(03)00220-8_BIB47 article-title: Elevated plasma lipid peroxides at the onset of non-affective psychosis publication-title: Biological Psychiatry doi: 10.1016/S0006-3223(97)00282-5 – volume: 8 start-page: 151 issue: 3 year: 1993 ident: 10.1016/S0165-1781(03)00220-8_BIB59 article-title: Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment publication-title: International Clinical Psychopharmacology doi: 10.1097/00004850-199300830-00003 – volume: 13 start-page: 261 issue: 2 year: 1987 ident: 10.1016/S0165-1781(03)00220-8_BIB30 article-title: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia publication-title: Schizophrenia Bulletin doi: 10.1093/schbul/13.2.261 |
SSID | ssj0002199 |
Score | 2.2714324 |
Snippet | Oxidative stress-mediated cell damage has been considered in the pathophysiology of schizophrenia. Abnormal findings have often been considered related to... |
SourceID | proquest pubmed pascalfrancis crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 109 |
SubjectTerms | Adult Adult and adolescent clinical studies Affect Antioxidant enzymes Antioxidants - metabolism Apolipoproteins A - blood Apolipoproteins B - blood Biological and medical sciences Bipolar Disorder - diagnosis Bipolar Disorder - enzymology Bipolar disorders Bipolar mood disorder Brief Psychiatric Rating Scale Catalase - metabolism Cell Membrane - metabolism Cell Membrane - pathology Cholesterol - blood Erythrocytes - enzymology Erythrocytes - pathology Essential fatty acids Fatty Acids, Essential - metabolism Fatty Acids, Unsaturated - metabolism Female Glutathione Peroxidase - metabolism Humans Lipid peroxides Male Medical sciences Mood disorders Oxidative Stress - physiology Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychoses Schizophrenia Schizophrenia - diagnosis Schizophrenia - enzymology Schizophrenia - physiopathology Severity of Illness Index Superoxide Dismutase - metabolism Triglycerides - blood Wechsler Scales |
Title | Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0165178103002208 https://dx.doi.org/10.1016/S0165-1781(03)00220-8 https://www.ncbi.nlm.nih.gov/pubmed/14656446 https://www.proquest.com/docview/71429723 |
Volume | 121 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1872-7123 dateEnd: 20191231 omitProxy: true ssIdentifier: ssj0002199 issn: 0165-1781 databaseCode: ACRLP dateStart: 19950131 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1872-7123 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002199 issn: 0165-1781 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1872-7123 dateEnd: 20191231 omitProxy: true ssIdentifier: ssj0002199 issn: 0165-1781 databaseCode: AIKHN dateStart: 19950131 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1872-7123 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002199 issn: 0165-1781 databaseCode: AKRWK dateStart: 19790701 isFulltext: true providerName: Library Specific Holdings |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Na9VAEB9KBRFE_PZVfe7Bgx7Sl2Q3Hz2Wankq7UULvS2b_YBAXxJMHvh68OQf7sxm09ceSsVTYNlZlpnJzG-ZL4D3QtM0JH0QaYoPipzbCEGsi9C5c5tUTjtLEd2T03x5Jr6eZ-c7cDTVwlBaZbD9o0331jqsLAI3F11dL75TIU5SlDQni8pFqeCXun-hTu__3qZ5pOMMSdoc0e5tFc94gl_8EPOP_pCovM0_PexUj1xz47iL2_Go90vHj-FRAJTscLzzE9ixzVO4fxJC5s_gzycPDHtrmKLMxl-1wS-zzeVmZXtcM2xlV_hmbiyjPuK4B4_r2ovNuump6yeCUcOcGoYNU7o2Pasb1l9L1dP-jKru6JHMVm1rmAktPVno2to_h7Pjzz-OllEYvRBpRGBD5KpUG5srdPBcxS4r4yqLE5WKokqdSkqqQM0FReWEQRtg8dGnDVlfxYXLsoy_gN2mbewrYLkpDVKmHuskrlJVUfC8SJw1yHF7MAMxMVzq0JecxmNcyGsJaHkmSU4y5tLLSZYz2L8i68bGHHcR5JM05VR1inZSouu4i7C8Iryhmv9COr-hNtubIspGbokZvJv0SOJ_TcEaFHe77mWRIFIoUj6Dl6N6bWmpxR1q-t7_3-s1PBiTEikt5w3sDj_X9i2Cq6Ga-79nDvcOv3xbnv4FZEgcXQ |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7SDbSFUvpKu22a6NBDe3DXD_mRY8iDTZPdSxPITch6gCFrm9oL3Z77wztjy7vJIST0ZBCeQYykmW-YF8AXrmgakjrwFMUHeRIZD0Gs9dC4RybIrbKGIrqzeTK94j-u4-stOBpqYSit0un-Xqd32tqtTJw0J3VRTH5SIU6QZjQni8pFsyewzWPUySPYPjw7n87XCjnsx0jS_x4RbAp5eibd4lc_-tbx8bL7TNSLWjYoONtPvLgfknam6fQVvHSYkh32234NW6Z8A09nLmr-Fv4ed9iwMZpJSm78XWj8MlP-WS1Mg2uaLcwC3ebSMGoljv8gu7q6WS3Lhhp_Ih7VzMq2XTGpCt2womTNrWw91fHIi5r8ZLaoKs206-rJXOPW5h1cnZ5cHk09N33BUwjCWs_modImkWjjI-nbOPPz2A9kyNM8tDLIqAg14RSY4xrVgEG_T2lSwDLiNo7jaAdGZVWaD8ASnWmkDDu4E9hc5mkaJWlgjUaJm4Mx8EHgQrnW5DQh40bcykFLYkHnJPxIdOcksjF8X5PVfW-OhwiS4TTFUHiKqlKg9XiIMFsT3rmdjyHdu3NtNjtFoI3S4mPYH-6RwKdN8Ro87mrZiDRAsJCG0Rje99drQ0td7tCR__j_-9qHZ9PL2YW4OJuff4LnfY4iZenswqj9tTSfEWu1-Z57S_8ADTsfCA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decreased+antioxidant+enzymes+and+membrane+essential+polyunsaturated+fatty+acids+in+schizophrenic+and+bipolar+mood+disorder+patients&rft.jtitle=Psychiatry+research&rft.au=Ranjekar%2C+Prabhakar+K&rft.au=Hinge%2C+Ashwini&rft.au=Hegde%2C+Mahabaleshwar+V&rft.au=Ghate%2C+Madhav&rft.date=2003-12-01&rft.issn=0165-1781&rft.volume=121&rft.issue=2&rft.spage=109&rft.epage=122&rft_id=info:doi/10.1016%2FS0165-1781%2803%2900220-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_S0165_1781_03_00220_8 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0165-1781&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0165-1781&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0165-1781&client=summon |